Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adaptive Biotechnologies CorpADPT · Entity 1126 | Chief People Officer | October 01, 2026 | October 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adaptive Biotechnologies Corp
Report date October 01, 2026 · Filed October 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 220,867 |
Ending reported balance
After 2026-10-01 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2026-10-01 · Exercise / conversion · Acquired 8,038 · Balance 228,905 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. Row 2 · 2026-10-01 · Exercise / conversion · Acquired 9,377 · Balance 238,282 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. Row 3 · 2026-10-01 · Exercise / conversion · Acquired 9,377 · Balance 247,659 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. Row 4 · 2026-10-01 · Sale · Disposed 8,094 · Balance 239,565 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. F2: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.22 to $28.22, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Row 5 · 2026-10-01 · Sale · Disposed 18,698 · Balance 220,867 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. F3: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.33 to $29.00, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.46 · Expires 2033-03-06 | Direct | 16,075 |
Reported balance
After 2026-10-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-10-01 · Exercise / conversion · Disposed 8,038 · Balance 16,075 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. F4: The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.99 · Expires 2034-03-04 | Direct | 56,259 |
Reported balance
After 2026-10-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-10-01 · Exercise / conversion · Disposed 9,377 · Balance 56,259 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. F5: The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.12 · Expires 2035-03-04 | Direct | 93,765 |
Reported balance
After 2026-10-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-10-01 · Exercise / conversion · Disposed 9,377 · Balance 93,765 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. F6: The options vested with respect to 1/4 of such shares on March 4, 2026, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. |
| Common StockSEC Table I · non-derivative | IndirectBy You Jin Lee (spouse) | 2,500 |
Reported balance
Holding disclosure · report date 2026-10-01 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 2,500 |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.
F2: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.22 to $28.22, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.33 to $29.00, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F4: The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
F5: The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
F6: The options vested with respect to 1/4 of such shares on March 4, 2026, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 12, 2026 Filed Jan 15, 2026 00:42 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 21,002 | $0.00 Strike: $8.46 | $0.00 |
DisclosureSEC source: 0001780660-26-000003 · primary_doc.xml · derivative · entry 9 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,074 Underlying: Common Stock · 21,002 shares Expires 2033-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. F4 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| January 12, 2026 Filed Jan 15, 2026 00:42 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 7,723 | $0.00 Strike: $12.14 | $0.00 |
DisclosureSEC source: 0001780660-26-000003 · primary_doc.xml · derivative · entry 8 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 177,615 Underlying: Common Stock · 7,723 shares Expires 2032-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. F3 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2023, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| January 12, 2026 Filed Jan 15, 2026 00:42 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 36,650 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001780660-26-000003 · primary_doc.xml · derivative · entry 7 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,500 Underlying: Common Stock · 36,650 shares Expires 2029-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. F2 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| January 12, 2026 Filed Jan 15, 2026 00:42 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 79,590 | $17.73 | $1,411,130.70 |
DisclosureSEC source: 0001780660-26-000003 · primary_doc.xml · nonDerivative · entry 5 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 315,978 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. Read SEC document |
| January 12, 2026 Filed Jan 15, 2026 00:42 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 14,215 | $3.99 | $56,717.85 |
DisclosureSEC source: 0001780660-26-000003 · primary_doc.xml · nonDerivative · entry 4 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 395,568 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. Read SEC document |
| January 12, 2026 Filed Jan 15, 2026 00:42 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 21,002 | $8.46 | $177,676.92 |
DisclosureSEC source: 0001780660-26-000003 · primary_doc.xml · nonDerivative · entry 3 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 381,353 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. Read SEC document |
| January 12, 2026 Filed Jan 15, 2026 00:42 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 7,723 | $12.14 | $93,757.22 |
DisclosureSEC source: 0001780660-26-000003 · primary_doc.xml · nonDerivative · entry 2 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 360,351 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. Read SEC document |
| January 12, 2026 Filed Jan 15, 2026 00:42 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 36,650 | $7.80 | $285,870.00 |
DisclosureSEC source: 0001780660-26-000003 · primary_doc.xml · nonDerivative · entry 1 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 352,628 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 00:52 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 3,125 | $0.00 Strike: $3.99 | $0.00 |
DisclosureSEC source: 0001780660-26-000001 · primary_doc.xml · derivative · entry 4 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 104,856 Underlying: Common Stock · 3,125 shares Expires 2034-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. F3 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 00:52 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 3,125 | $16.08 | $50,250.00 |
DisclosureSEC source: 0001780660-26-000001 · primary_doc.xml · nonDerivative · entry 2 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 315,978 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. F2 · price: The price reported for this transaction is a weighted -average price. The shares were sold in multiple transactions ranging from $15.77 to $16.40, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| January 02, 2026 Filed Jan 7, 2026 00:52 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 3,125 | $3.99 | $12,468.75 |
DisclosureSEC source: 0001780660-26-000001 · primary_doc.xml · nonDerivative · entry 1 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 319,103 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. Read SEC document |
| December 22, 2025 Filed Dec 29, 2025 23:27 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 1,100 | $0.00 Strike: $3.99 | $0.00 |
DisclosureSEC source: 0001780660-25-000003 · primary_doc.xml · derivative · entry 8 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 109,075 Underlying: Common Stock · 1,100 shares Expires 2034-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. F5 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| December 22, 2025 Filed Dec 29, 2025 23:27 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 2,194 | $0.00 Strike: $8.46 | $0.00 |
DisclosureSEC source: 0001780660-25-000003 · primary_doc.xml · derivative · entry 7 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,982 Underlying: Common Stock · 2,194 shares Expires 2033-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. F4 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| December 22, 2025 Filed Dec 29, 2025 23:27 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 1,100 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001780660-25-000003 · primary_doc.xml · derivative · entry 6 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 112,150 Underlying: Common Stock · 1,100 shares Expires 2029-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 22, 2025 Filed Dec 29, 2025 23:27 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 4,394 | $17.50 | $76,895.00 |
DisclosureSEC source: 0001780660-25-000003 · primary_doc.xml · nonDerivative · entry 4 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 315,978 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $17.49 to $17.50, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| December 22, 2025 Filed Dec 29, 2025 23:27 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 1,100 | $3.99 | $4,389.00 |
DisclosureSEC source: 0001780660-25-000003 · primary_doc.xml · nonDerivative · entry 3 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 320,372 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. Read SEC document |
| December 22, 2025 Filed Dec 29, 2025 23:27 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 2,194 | $8.46 | $18,561.24 |
DisclosureSEC source: 0001780660-25-000003 · primary_doc.xml · nonDerivative · entry 2 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 319,272 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. Read SEC document |
| December 22, 2025 Filed Dec 29, 2025 23:27 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 1,100 | $7.80 | $8,580.00 |
DisclosureSEC source: 0001780660-25-000003 · primary_doc.xml · nonDerivative · entry 1 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 317,078 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. Read SEC document |
| December 22, 2025 Filed Jan 8, 2026 01:52 UTC Amendment | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 2,194 | $0.00 Strike: $3.99 | $0.00 |
DisclosureSEC source: 0001780660-26-000002 · primary_doc.xml · derivative · entry 8 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 107,981 Underlying: Common Stock · 2,194 shares Expires 2034-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. F5 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| December 22, 2025 Filed Jan 8, 2026 01:52 UTC Amendment | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 1,100 | $0.00 Strike: $8.46 | $0.00 |
DisclosureSEC source: 0001780660-26-000002 · primary_doc.xml · derivative · entry 7 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 108,076 Underlying: Common Stock · 1,100 shares Expires 2033-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. F4 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| December 22, 2025 Filed Jan 8, 2026 01:52 UTC Amendment | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 1,100 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001780660-26-000002 · primary_doc.xml · derivative · entry 6 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 112,150 Underlying: Common Stock · 1,100 shares Expires 2029-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 22, 2025 Filed Jan 8, 2026 01:52 UTC Amendment | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 4,394 | $17.50 | $76,895.00 |
DisclosureSEC source: 0001780660-26-000002 · primary_doc.xml · nonDerivative · entry 4 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 315,978 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. F2 · price: The price reported for this transaction is a weighted -average price. The shares were sold in multiple transactions ranging from $17.49 to $17.50, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| December 22, 2025 Filed Jan 8, 2026 01:52 UTC Amendment | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 2,194 | $3.99 | $8,754.06 |
DisclosureSEC source: 0001780660-26-000002 · primary_doc.xml · nonDerivative · entry 3 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 320,372 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. Read SEC document |
| December 22, 2025 Filed Jan 8, 2026 01:52 UTC Amendment | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 1,100 | $8.46 | $9,306.00 |
DisclosureSEC source: 0001780660-26-000002 · primary_doc.xml · nonDerivative · entry 2 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 318,178 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. Read SEC document |
| December 22, 2025 Filed Jan 8, 2026 01:52 UTC Amendment | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 1,100 | $7.80 | $8,580.00 |
DisclosureSEC source: 0001780660-26-000002 · primary_doc.xml · nonDerivative · entry 1 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 317,078 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. Read SEC document |
| December 15, 2025 Filed Dec 18, 2025 00:06 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 39,849 | $0.00 Strike: $3.99 | $0.00 |
DisclosureSEC source: 0001780660-25-000002 · primary_doc.xml · derivative · entry 8 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 110,175 Underlying: Common Stock · 39,849 shares Expires 2034-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. F5 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| December 15, 2025 Filed Dec 18, 2025 00:06 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 19,423 | $0.00 Strike: $8.46 | $0.00 |
DisclosureSEC source: 0001780660-25-000002 · primary_doc.xml · derivative · entry 7 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 109,176 Underlying: Common Stock · 19,423 shares Expires 2033-03-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. F4 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| December 15, 2025 Filed Dec 18, 2025 00:06 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 37,750 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001780660-25-000002 · primary_doc.xml · derivative · entry 6 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 113,250 Underlying: Common Stock · 37,750 shares Expires 2029-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 15, 2025 Filed Dec 18, 2025 00:06 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 113,890 | $15.57 | $1,773,267.30 |
DisclosureSEC source: 0001780660-25-000002 · primary_doc.xml · nonDerivative · entry 4 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 315,978 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. F2 · price: The price reported for this transaction is a weighted -average price. The shares were sold in multiple transactions ranging from $15.37 to $16.03, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| December 15, 2025 Filed Dec 18, 2025 00:06 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 39,849 | $3.99 | $158,997.51 |
DisclosureSEC source: 0001780660-25-000002 · primary_doc.xml · nonDerivative · entry 3 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 429,868 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. Read SEC document |
| December 15, 2025 Filed Dec 18, 2025 00:06 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 19,423 | $8.46 | $164,318.58 |
DisclosureSEC source: 0001780660-25-000002 · primary_doc.xml · nonDerivative · entry 2 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 390,019 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. Read SEC document |
| December 15, 2025 Filed Dec 18, 2025 00:06 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 37,750 | $7.80 | $294,450.00 |
DisclosureSEC source: 0001780660-25-000002 · primary_doc.xml · nonDerivative · entry 1 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 370,596 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 00:22 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 13,790 | $6.99 | $96,392.10 |
DisclosureSEC source: 0001062993-25-004818 · form4.xml · nonDerivative · entry 3 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 332,846 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 00:22 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 7,085 | $6.98 | $49,453.30 |
DisclosureSEC source: 0001062993-25-004818 · form4.xml · nonDerivative · entry 2 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 346,636 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 04, 2025 Filed Mar 7, 2025 00:22 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantStock Option (right to buy) · Derivative | 150,024 | $0.00 Strike: $8.12 | $0.00 |
DisclosureSEC source: 0001062993-25-004818 · form4.xml · derivative · entry 5 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,024 Underlying: Common Stock · 150,024 shares Expires 2035-03-04 F2 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on March 4, 2026, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| March 04, 2025 Filed Mar 7, 2025 00:22 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 99,976 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-004818 · form4.xml · nonDerivative · entry 1 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 353,721 Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 00:42 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 1,813 | $3.44 | $6,236.72 |
DisclosureSEC source: 0001062993-24-005763 · form4.xml · nonDerivative · entry 3 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 253,745 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 00:42 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 12,887 | $3.43 | $44,202.41 |
DisclosureSEC source: 0001062993-24-005763 · form4.xml · nonDerivative · entry 2 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 255,558 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 04, 2024 Filed Mar 7, 2024 00:42 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantStock Option (right to buy) · Derivative | 150,024 | $0.00 Strike: $3.99 | $0.00 |
DisclosureSEC source: 0001062993-24-005763 · form4.xml · derivative · entry 5 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,024 Underlying: Common Stock · 150,024 shares Expires 2034-03-04 F2 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| March 04, 2024 Filed Mar 7, 2024 00:42 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 99,976 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-005763 · form4.xml · nonDerivative · entry 1 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 268,445 Read SEC document |
| March 06, 2023 Filed Mar 9, 2023 01:04 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantStock Option (right to buy) · Derivative | 128,599 | $0.00 Strike: $8.46 | $0.00 |
DisclosureSEC source: 0001062993-23-006329 · form4.xml · derivative · entry 4 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,599 Underlying: Common Stock · 128,599 shares Expires 2033-03-06 F2 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| March 06, 2023 Filed Mar 9, 2023 01:04 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 6,816 | $8.57 | $58,413.12 |
DisclosureSEC source: 0001062993-23-006329 · form4.xml · nonDerivative · entry 2 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,469 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 06, 2023 Filed Mar 9, 2023 01:04 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 85,697 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-006329 · form4.xml · nonDerivative · entry 1 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,285 Read SEC document |
| March 08, 2022 Filed Mar 10, 2022 21:05 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 3,582 | $11.44 | $40,978.08 |
DisclosureSEC source: 0001209191-22-017839 · doc4.xml · nonDerivative · entry 1 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,588 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2021. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $11.29 to 11.65, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 02:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 1,569 | $12.01 | $18,843.69 |
DisclosureSEC source: 0001209191-22-017395 · doc4.xml · nonDerivative · entry 2 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,170 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 04, 2022 Filed Mar 9, 2022 02:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantStock Option (Right to Buy) · Derivative | 185,338 | $0.00 Strike: $12.14 | $0.00 |
DisclosureSEC source: 0001209191-22-017395 · doc4.xml · derivative · entry 4 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,338 Underlying: Common Stock · 185,338 shares Expires 2032-03-04 F2 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on March 4, 2023, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| March 04, 2022 Filed Mar 9, 2022 02:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 74,135 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017395 · doc4.xml · nonDerivative · entry 1 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,739 Read SEC document |
| May 14, 2021 Filed May 18, 2021 00:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right To Buy) · Derivative | 2,000 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001209191-21-033313 · doc4.xml · derivative · entry 4 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,000 Underlying: Common Stock · 2,000 shares Expires 2029-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 18, 2020. F2 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on May 6, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| May 14, 2021 Filed May 18, 2021 00:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 2,000 | $33.80 | $67,600.00 |
DisclosureSEC source: 0001209191-21-033313 · doc4.xml · nonDerivative · entry 2 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,604 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 18, 2020. Read SEC document |
| May 14, 2021 Filed May 18, 2021 00:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 2,000 | $7.80 | $15,600.00 |
DisclosureSEC source: 0001209191-21-033313 · doc4.xml · nonDerivative · entry 1 LO FRANCIS · CIK 0001780660 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,604 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 18, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.